Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease.
about
Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study.Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease.Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's diseaseClinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study.Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn's Disease.Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.Early remission status predicts long-term outcomes in patients with Crohn's disease treated with certolizumab pegol.Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease.Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.Improving the sensitivity and specificity of a bioanalytical assay for the measurement of certolizumab pegol.Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis.
P2860
Q30248641-B99FA3A6-C595-4380-823F-F504F1ADCE78Q31113830-B110B4AC-79E0-4C35-9C76-AA35B69ED789Q36347059-0CCF2955-B8A9-4CA7-AB6B-3EE8E0366DECQ37275504-43281730-7891-429E-8B30-EDE7218AD266Q38410616-F3A856A5-F274-43EA-9027-4718F03E7F79Q38869663-1CA6D9E5-0C48-46EF-81F8-6ED1EE4FCDD4Q38883761-AC6C8379-303F-4F21-AAF3-91840E1A3190Q38987211-D7017F7A-282C-436B-AB05-2BB414734CAAQ40634478-644A7889-F76A-4FFE-856F-26A8706468BCQ45951213-B6579404-6668-40BF-A7A0-198FFBEFC3D9Q46756144-DF8DAD56-01B9-43D0-B6A9-FBCEA1152EC6Q47798181-91920D41-FB99-4440-9334-0503FC95D40DQ53164680-E448A540-3CBF-4AA2-B294-8EBB6F06B0C5Q54940383-425A367D-8523-4A59-AF8A-33D0A7CE618B
P2860
Population pharmacokinetic analysis of certolizumab pegol in patients with Crohn's disease.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Population pharmacokinetic ana ...... patients with Crohn's disease.
@en
type
label
Population pharmacokinetic ana ...... patients with Crohn's disease.
@en
prefLabel
Population pharmacokinetic ana ...... patients with Crohn's disease.
@en
P2093
P2860
P356
P1476
Population pharmacokinetic ana ...... patients with Crohn's disease
@en
P2093
Brian G Feagen
Christian Laveille
Gerry Parker
Gordana Kosutic
Ruth Oliver
William J Sandborn
P2860
P304
P356
10.1002/JCPH.491
P50
P577
2015-04-13T00:00:00Z